AI Article Synopsis
- Immune-related adverse events (irAEs) are significant issues for cancer patients undergoing treatment with immune checkpoint inhibitors (ICIs).
- Pancreas-specific irAEs are uncommon but can present with various symptoms including elevated pancreatic enzymes, pancreatitis, and diabetes.
- A study found 22 cases of pancreas-specific irAEs in 21 lung cancer patients, with injuries affecting 13 patients, pancreatitis occurring in 4, and diabetes developing in 5.
Article Abstract
Immune-related adverse events (irAEs) are one of the key concerns in cancer patients treated with immune checkpoint inhibitors (ICIs). Among the various irAEs, pancreas-specific irAE is a rare but special one with a variety of manifestations, such as pancreatic enzymes elevation, pancreatitis as well as diabetes. The current study reported 22 pancreas-specific irAEs in 21 patients with lung cancer, including pancreatic injury in 13 patients, pancreatitis in four patients and diabetes mellitus in five patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421295 | PMC |
| http://dx.doi.org/10.1080/1750743X.2024.2354108 | DOI Listing |
Publication Analysis
Top Keywords
immune-related adverse
8
adverse events
8
patients lung
8
lung cancer
8
patients
6
pancreas-specific immune-related
4
events patients
4
cancer case
4
case series
4
series study
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!